Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer

Various regimens including molecular targeted agents have been examined in patients with cisplatin (CDDP)-resistant urothelial cancer (UC). However, some studies have been stopped owing to the development of severe adverse events. The main aim of this study was to examine the anticancer effects, cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Miyata, Yasuyoshi, Asai, Akihiro, Mitsunari, Kensuke, Matsuo, Tomohiro, Ohba, Kojiro, Sakai, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2015
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550651/
https://www.ncbi.nlm.nih.gov/pubmed/26310889
http://dx.doi.org/10.1007/s12032-015-0683-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550651/
https://www.ncbi.nlm.nih.gov/pubmed/26310889
http://dx.doi.org/10.1007/s12032-015-0683-y

Ejemplares similares